Nykode Therapeutics As (VACBF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the NICODE Therapeutics Q1 2026 Financial Results Presentation. At this time, all participants are in listening mode. A question and answer session will follow the formal presentation. You may ask a question at any time by typing it into the Ask a Question feature on your screen. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to NICODE CEO, Michael Engsig. Please go ahead, sir. Thank you very much, Kevin. And also from my side, a very warm welcome to all our listeners to this, our first quarter webcast on this beautiful summer day in Oslo. A quick look at our forward-looking statement, which I think you are all familiar. On that basis, we will move forward. As usual, it is a pleasure to have with me today, Anita Fredriksson, our co-founder, chief scientific officer, and head of business development As well as how our chief financial officer. Taking you through the highlights of of the quarter that the deep dive into some of the data and of course, the financial numbers also. So, for the new listeners, a very quick recap, my code is a chemical stage immunotherapy company. focus on leveraging our antigen-presenting cell targeted immunotherapy platform to discover new immunotherapies within oncology and autoimmune diseases. Our lead asset is Abisuba, which we are developing in first-line head and neck. But we also have very high conviction in EB10neo, our individualized neoantigen therapy platform, as well as our autoimmune disease program. We're well capitalized with funding taking us into 2028, which is on the other side of all important inflection points. It's been a busy quarter with a lot of progress, in particular on Abhisuva, but also interesting movement on our other programs. For Abhisuva, ...